Purpose: A sensitive assay to detect minimal residual disease in neuroblastoma is necessary for accurate assessment of disease status and optimal treatment. In this study, we compared the usefulness of sensitive methods, flow cytometry and RT-PCR for the detection of minimal residual disease in neuroblastoma. Methods: Eighteen patients who were newly diagnosed and treated at Severance Hospital since 1999 were included in this study. Samples from bone marrow, peripheral blood, and peripheral blood stem cell product were examined for tumor cell contamination by RT-PCR (TH RT-PCR) to detect tyrosine hydroxylase mRNA and by flow cytometry identifying CD9+/CD56+/CD45- cells. Results: We analyzed 20 cases from 18 patients, which were assayed ...
PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of canc...
PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of canc...
Amplification of the MYCN gene in neuroblastomas is a potent biological marker of highly aggressive ...
BACKGROUND: Because the cytomorphologic examination of bone marrow (BM) aspirates appears not sensit...
BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can...
BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can...
With a continuous development of molecular-biology methods more attention has been paid to molecular...
Neuroblastoma is the third most common childhood cancer. The presence of metastatic spread at diagno...
PURPOSE: The purpose of this study was to establish a sensitive and semiquantitative method for the ...
PURPOSE: Circulating tumor cells (CTCs) serve as noninvasive tumor biomarkers in many types of canc...
In neuroblastoma (NB) patients, minimal residual disease (MRD) can be detected by real-time quantita...
Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neur...
Background: Bone marrow involvement is an important aspect of determining staging of disease and tre...
Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neur...
Purpose: The N-myc amplification is one of well known poor prognostic markers in neurblastoma. Becau...
PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of canc...
PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of canc...
Amplification of the MYCN gene in neuroblastomas is a potent biological marker of highly aggressive ...
BACKGROUND: Because the cytomorphologic examination of bone marrow (BM) aspirates appears not sensit...
BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can...
BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can...
With a continuous development of molecular-biology methods more attention has been paid to molecular...
Neuroblastoma is the third most common childhood cancer. The presence of metastatic spread at diagno...
PURPOSE: The purpose of this study was to establish a sensitive and semiquantitative method for the ...
PURPOSE: Circulating tumor cells (CTCs) serve as noninvasive tumor biomarkers in many types of canc...
In neuroblastoma (NB) patients, minimal residual disease (MRD) can be detected by real-time quantita...
Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neur...
Background: Bone marrow involvement is an important aspect of determining staging of disease and tre...
Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neur...
Purpose: The N-myc amplification is one of well known poor prognostic markers in neurblastoma. Becau...
PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of canc...
PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of canc...
Amplification of the MYCN gene in neuroblastomas is a potent biological marker of highly aggressive ...